Mesenchymal stem cell-derived exosomes for clinical use

Area of Science:

• * Regenerative Medicine
• * Cell Biology
• * Immunology

Background:

• * Mesenchymal stem/stromal cells (MSCs) are utilized for cellular therapy due to potent immunosuppressive and regenerative properties.
• * MSC efficacy is largely attributed to paracrine signaling, particularly through secreted extracellular vesicles called exosomes.
• * MSC-derived exosomes are emerging as a promising cell-free therapeutic alternative to live MSCs.

Purpose of the Study:

• * To review ongoing clinical trials investigating MSC-derived exosomes.
• * To highlight their therapeutic potential in gene delivery, regenerative medicine, and immunomodulation.
• * To summarize current limitations and future prospects of this cell-free strategy.

Main Methods:

• * Comprehensive review of current clinical trials involving MSC-derived exosomes.
• * Analysis of exosome-mediated mechanisms in gene delivery, regeneration, and immunomodulation.
• * Assessment of the advantages and limitations of exosome-based cell-free therapy.

Main Results:

• * Clinical trials are actively exploring MSC-derived exosomes for various therapeutic applications.
• * Exosomes facilitate MSCs' therapeutic actions through paracrine mechanisms.
• * Cell-free exosome therapy may mitigate risks associated with live MSC infusions.

Conclusions:

• * MSC-derived exosomes represent a promising cell-free therapeutic approach.
• * Further research and clinical evaluation are necessary to fully realize their potential.
• * Exosome therapy offers a potentially safer and more effective alternative in regenerative medicine and immunomodulation.